Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
- Autores
- Raiden, Silvina Claudia; Geffner, Jorge Raúl
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccination
Fil: Raiden, Silvina Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); Argentina
Fil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina - Materia
-
ANTIBODY RESPONSES
SPUTNIK V VACCINE
COVID-19 - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/161413
Ver los metadatos del registro completo
id |
CONICETDig_616ba3ebfd9877662404a1589b668708 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/161413 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2Raiden, Silvina ClaudiaGeffner, Jorge RaúlANTIBODY RESPONSESSPUTNIK V VACCINECOVID-19https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccinationFil: Raiden, Silvina Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); ArgentinaFil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaElsevier2022-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/161413Raiden, Silvina Claudia; Geffner, Jorge Raúl; Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2; Elsevier; The Lancet Regional Health - Americas; 6; 100172; 2-2022; 1-22667-193XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.thelancet.com/journals/lanam/article/PIIS2667-193X2100168-X/fulltext#:~:text=Follow%2Dup%20of%20vaccinated%20individuals,at%20180%20days%20after%20vaccination.info:eu-repo/semantics/altIdentifier/doi/10.1016/j.lana.2021.100172info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2667193X2100168Xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:51:16Zoai:ri.conicet.gov.ar:11336/161413instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:51:16.414CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2 |
title |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2 |
spellingShingle |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2 Raiden, Silvina Claudia ANTIBODY RESPONSES SPUTNIK V VACCINE COVID-19 |
title_short |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2 |
title_full |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2 |
title_fullStr |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2 |
title_full_unstemmed |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2 |
title_sort |
Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2 |
dc.creator.none.fl_str_mv |
Raiden, Silvina Claudia Geffner, Jorge Raúl |
author |
Raiden, Silvina Claudia |
author_facet |
Raiden, Silvina Claudia Geffner, Jorge Raúl |
author_role |
author |
author2 |
Geffner, Jorge Raúl |
author2_role |
author |
dc.subject.none.fl_str_mv |
ANTIBODY RESPONSES SPUTNIK V VACCINE COVID-19 |
topic |
ANTIBODY RESPONSES SPUTNIK V VACCINE COVID-19 |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccination Fil: Raiden, Silvina Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); Argentina Fil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina |
description |
The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccination |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-02 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/161413 Raiden, Silvina Claudia; Geffner, Jorge Raúl; Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2; Elsevier; The Lancet Regional Health - Americas; 6; 100172; 2-2022; 1-2 2667-193X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/161413 |
identifier_str_mv |
Raiden, Silvina Claudia; Geffner, Jorge Raúl; Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2; Elsevier; The Lancet Regional Health - Americas; 6; 100172; 2-2022; 1-2 2667-193X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.thelancet.com/journals/lanam/article/PIIS2667-193X2100168-X/fulltext#:~:text=Follow%2Dup%20of%20vaccinated%20individuals,at%20180%20days%20after%20vaccination. info:eu-repo/semantics/altIdentifier/doi/10.1016/j.lana.2021.100172 info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2667193X2100168X |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269084688842752 |
score |
13.13397 |